Application of chitin and chitosan derivatives in the pharmaceutical field

Yoshinori Kato, Hiraku Onishi, Yoshiharu Machida

Research output: Contribution to journalArticle

Abstract

Chitin and chitosan derivatives are used as excipients and drug carriers in the pharmaceutical field. Their derivatization contributed to expansion of application and decrease toxicity. Chitosan is used as an excipient in oral dosage form. Chitosan tablet can exhibit a sustained drug release compared to commercial products. Films prepared using chitin or chitosan have been developed as wound dressings, oral mucoadhesive and water-resisting adhesive by virtue of their release characteristics and adhesion. Intratumoral administration of gadopentetic acid-chitosan complex nanoparticles (approximately 430 nm in diameter) has been more effective for gadolinium neutron-capture therapy compared with a group treated with the solution. Compared to intragastrical feeding with diphtheria toxoid (DT) in PBS, a strong enhancement of the systemic (IgG) and local (IgA) immune responses against DT has been observed in mice fed with DT loaded chitosan microparticles (approximately 4.7 μm in size). When DNA-loaded chitosan microspheres (1.15 -1.28 μm) were intramuscularly administrated into mice, high β-galactosidase and luciferase productions were obtained even after a long post-transfection period (12 weeks). N-Succinyl-chitosan (Suc-Chi) has been studied for cancer chemotherapy as a drug carrier and the conjugates of mitomycin C with Suc-Chi exhibited good antitumor activities against various tumors. Furthermore, trimethyl-chitosan and monocarboxymethyl-chitosan has been shown to be effective as intestinal absorption enhancers due to their physiological properties. Chitosan-thioglycolic acid conjugates has been found to be a promising candidate as scaffold material in tissue engineering due to their physicochemical properties. This review summarizes the application of chitin and chitosan derivatives for hospital preparations and drug carriers.

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalCurrent Pharmaceutical Biotechnology
Volume4
Issue number5
DOIs
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Chitin
Chitosan
Pharmaceutical Preparations
Diphtheria Toxoid
Drug Carriers
Excipients
Neutron Capture Therapy
Galactosidases
Gadolinium DTPA
Intestinal Absorption
Dosage Forms
Gadolinium
Mitomycin
Tissue Engineering
Bandages
Luciferases
Microspheres
Adhesives
Nanoparticles
Tablets

Keywords

  • Absorption enhancer
  • Chitin and chitosan derivatives
  • Conjugates
  • Micro/nanoparticles
  • Oral dosage from
  • Oral vaccination
  • Scaffold material
  • Wound dressing

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Molecular Medicine
  • Biotechnology

Cite this

Application of chitin and chitosan derivatives in the pharmaceutical field. / Kato, Yoshinori; Onishi, Hiraku; Machida, Yoshiharu.

In: Current Pharmaceutical Biotechnology, Vol. 4, No. 5, 10.2003, p. 303-309.

Research output: Contribution to journalArticle

Kato, Yoshinori ; Onishi, Hiraku ; Machida, Yoshiharu. / Application of chitin and chitosan derivatives in the pharmaceutical field. In: Current Pharmaceutical Biotechnology. 2003 ; Vol. 4, No. 5. pp. 303-309.
@article{b397b3cc37564600ae381c4d9ad3eb3b,
title = "Application of chitin and chitosan derivatives in the pharmaceutical field",
abstract = "Chitin and chitosan derivatives are used as excipients and drug carriers in the pharmaceutical field. Their derivatization contributed to expansion of application and decrease toxicity. Chitosan is used as an excipient in oral dosage form. Chitosan tablet can exhibit a sustained drug release compared to commercial products. Films prepared using chitin or chitosan have been developed as wound dressings, oral mucoadhesive and water-resisting adhesive by virtue of their release characteristics and adhesion. Intratumoral administration of gadopentetic acid-chitosan complex nanoparticles (approximately 430 nm in diameter) has been more effective for gadolinium neutron-capture therapy compared with a group treated with the solution. Compared to intragastrical feeding with diphtheria toxoid (DT) in PBS, a strong enhancement of the systemic (IgG) and local (IgA) immune responses against DT has been observed in mice fed with DT loaded chitosan microparticles (approximately 4.7 μm in size). When DNA-loaded chitosan microspheres (1.15 -1.28 μm) were intramuscularly administrated into mice, high β-galactosidase and luciferase productions were obtained even after a long post-transfection period (12 weeks). N-Succinyl-chitosan (Suc-Chi) has been studied for cancer chemotherapy as a drug carrier and the conjugates of mitomycin C with Suc-Chi exhibited good antitumor activities against various tumors. Furthermore, trimethyl-chitosan and monocarboxymethyl-chitosan has been shown to be effective as intestinal absorption enhancers due to their physiological properties. Chitosan-thioglycolic acid conjugates has been found to be a promising candidate as scaffold material in tissue engineering due to their physicochemical properties. This review summarizes the application of chitin and chitosan derivatives for hospital preparations and drug carriers.",
keywords = "Absorption enhancer, Chitin and chitosan derivatives, Conjugates, Micro/nanoparticles, Oral dosage from, Oral vaccination, Scaffold material, Wound dressing",
author = "Yoshinori Kato and Hiraku Onishi and Yoshiharu Machida",
year = "2003",
month = "10",
doi = "10.2174/1389201033489748",
language = "English (US)",
volume = "4",
pages = "303--309",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Application of chitin and chitosan derivatives in the pharmaceutical field

AU - Kato, Yoshinori

AU - Onishi, Hiraku

AU - Machida, Yoshiharu

PY - 2003/10

Y1 - 2003/10

N2 - Chitin and chitosan derivatives are used as excipients and drug carriers in the pharmaceutical field. Their derivatization contributed to expansion of application and decrease toxicity. Chitosan is used as an excipient in oral dosage form. Chitosan tablet can exhibit a sustained drug release compared to commercial products. Films prepared using chitin or chitosan have been developed as wound dressings, oral mucoadhesive and water-resisting adhesive by virtue of their release characteristics and adhesion. Intratumoral administration of gadopentetic acid-chitosan complex nanoparticles (approximately 430 nm in diameter) has been more effective for gadolinium neutron-capture therapy compared with a group treated with the solution. Compared to intragastrical feeding with diphtheria toxoid (DT) in PBS, a strong enhancement of the systemic (IgG) and local (IgA) immune responses against DT has been observed in mice fed with DT loaded chitosan microparticles (approximately 4.7 μm in size). When DNA-loaded chitosan microspheres (1.15 -1.28 μm) were intramuscularly administrated into mice, high β-galactosidase and luciferase productions were obtained even after a long post-transfection period (12 weeks). N-Succinyl-chitosan (Suc-Chi) has been studied for cancer chemotherapy as a drug carrier and the conjugates of mitomycin C with Suc-Chi exhibited good antitumor activities against various tumors. Furthermore, trimethyl-chitosan and monocarboxymethyl-chitosan has been shown to be effective as intestinal absorption enhancers due to their physiological properties. Chitosan-thioglycolic acid conjugates has been found to be a promising candidate as scaffold material in tissue engineering due to their physicochemical properties. This review summarizes the application of chitin and chitosan derivatives for hospital preparations and drug carriers.

AB - Chitin and chitosan derivatives are used as excipients and drug carriers in the pharmaceutical field. Their derivatization contributed to expansion of application and decrease toxicity. Chitosan is used as an excipient in oral dosage form. Chitosan tablet can exhibit a sustained drug release compared to commercial products. Films prepared using chitin or chitosan have been developed as wound dressings, oral mucoadhesive and water-resisting adhesive by virtue of their release characteristics and adhesion. Intratumoral administration of gadopentetic acid-chitosan complex nanoparticles (approximately 430 nm in diameter) has been more effective for gadolinium neutron-capture therapy compared with a group treated with the solution. Compared to intragastrical feeding with diphtheria toxoid (DT) in PBS, a strong enhancement of the systemic (IgG) and local (IgA) immune responses against DT has been observed in mice fed with DT loaded chitosan microparticles (approximately 4.7 μm in size). When DNA-loaded chitosan microspheres (1.15 -1.28 μm) were intramuscularly administrated into mice, high β-galactosidase and luciferase productions were obtained even after a long post-transfection period (12 weeks). N-Succinyl-chitosan (Suc-Chi) has been studied for cancer chemotherapy as a drug carrier and the conjugates of mitomycin C with Suc-Chi exhibited good antitumor activities against various tumors. Furthermore, trimethyl-chitosan and monocarboxymethyl-chitosan has been shown to be effective as intestinal absorption enhancers due to their physiological properties. Chitosan-thioglycolic acid conjugates has been found to be a promising candidate as scaffold material in tissue engineering due to their physicochemical properties. This review summarizes the application of chitin and chitosan derivatives for hospital preparations and drug carriers.

KW - Absorption enhancer

KW - Chitin and chitosan derivatives

KW - Conjugates

KW - Micro/nanoparticles

KW - Oral dosage from

KW - Oral vaccination

KW - Scaffold material

KW - Wound dressing

UR - http://www.scopus.com/inward/record.url?scp=0141504461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141504461&partnerID=8YFLogxK

U2 - 10.2174/1389201033489748

DO - 10.2174/1389201033489748

M3 - Article

C2 - 14529420

AN - SCOPUS:0141504461

VL - 4

SP - 303

EP - 309

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 5

ER -